Trial of Montelukast for Treatment of Acute Bronchiolitis

NCT ID: NCT00863317

Last Updated: 2015-07-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

141 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary rationale for this study is to evaluate the effect of once daily montelukast on duration of acute illness in infants with first-time bronchiolitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiolitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

montelukast sodium

4mg granules PO QD for 14 days

Group Type EXPERIMENTAL

montelukast sodium

Intervention Type DRUG

4mg granules daily for 14 days

Placebo

Sucrose granules PO QD for 14 days

Group Type PLACEBO_COMPARATOR

sucrose

Intervention Type OTHER

table sugar as placebo daily for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

montelukast sodium

4mg granules daily for 14 days

Intervention Type DRUG

sucrose

table sugar as placebo daily for 14 days

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

singulair

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female infants aged 3 to 12 months of age
* Diagnosis by emergency physician of bronchiolitis

Exclusion Criteria

* Any previous episode, as determined by a physician, of wheezing, bronchiolitis or asthma
* Any history of previous bronchodilator use prior to this illness
* Treatment with corticosteroids in the 14 days prior to the current illness
* Immunosuppression
* Immunodeficiency
* Caregiver does not speak English
* Diagnosis by the treating ED physician of croup
* Diagnosis by the treating ED physician of pneumonia
* Caregiver does not have access to a telephone
Minimum Eligible Age

3 Months

Maximum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical College of Wisconsin

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Frank Petruzella

Pediatric Emergency Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marc Gorelick, MD, MSCE

Role: PRINCIPAL_INVESTIGATOR

Medical College of Wisconsin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's Hospital of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IND 103263

Identifier Type: OTHER

Identifier Source: secondary_id

FDP-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hypertonic Saline for Acute Bronchiolitis
NCT01247064 COMPLETED PHASE4
Isotonic Saline for Children With Bronchiolitis
NCT05902702 NOT_YET_RECRUITING NA